Fachliteratur Gastroenterologie: Leber

Fr | De

Feedback | Impressum | Sitemap

Keine Artikel ausgewählt!

Warenkorb

Sie sind hier: Fachliteratursuche » Leber

08. Mai 2026

Abklärungen / Diagnostik

Therapien

Guidelines

Fortbildung

News / Journalscreening

Schrift:

Seite 1 von 12748


	Artikel 1 - 20 / 254949

	Comparison of outcomes of second-line durvalumab plus tremelimumab versus lenvatinib following first-line atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. PLoS One Nishioka C, Tahata Y, Maesaka K, Kai M, Shirai K, Murai K, Makino Y, Saito Y, Nozaki Y, Nakabori T, Ishida H, Yakushijin T, Iio S, Tatsumi N, Imanaka K, Kakita N, Sakamori R, Hosui A, Miyazaki M, Matsumoto K, Nakahara M, Doi Y, Sakakibara M, Hikita H, Kodama T, Takehara T. PMID: 42096473 [PubMed - indexed for MEDLINE]
	Identification and functional analysis of key miRNAs and target genes associated with failure of HBV mother-to-child transmission prevention. PLoS One He Q, Zou X, Zheng C, Zhang J, Li J, Hu L, Zeng T, Huang Z, Zeng P, Wei J, Cui H, Su Y, Li H. PMID: 42096447 [PubMed - indexed for MEDLINE]
	Molecular insights into the mechanisms of occult hepatitis B virus infection. Arch Virol Mahdavi S, Abyazi MA, Gouvarchin Ghaleh HE, Golmohammadi R, Salimi Jeda A. PMID: 42096075 [PubMed - indexed for MEDLINE]
	Gut dysbiosis and nitric oxide dysregulation in cirrhosis progression: mechanistic insights and pathophysiological implications. J Physiol Biochem R, , R, Trella , Nenu I. PMID: 42095982 [PubMed - indexed for MEDLINE]
	Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Virus Infection in the High-Replicative Low-Inflammatory Phase: A 48-Week Randomized Controlled Trial. J Med Virol Luo Q, Xu R, Zhang Y, Xu W, Li X, Lai J, Li J, Zheng X, Deng H, Chen L, Zhu X, Xie C, Peng L. PMID: 42095461 [PubMed - indexed for MEDLINE]
	From Bench to Bedside: Multifunctional Nanoplatforms in the Fight Against Non-alcoholic Fatty Liver Disease. Int J Nanomedicine Zhao Y, Wang L, Zhu S, Feng R, Zhang W. PMID: 42094738 [PubMed - indexed for MEDLINE]
	Unraveling the pleiotropic effects of CCR2-dependent signal transduction in fibrosis development. Theranostics Sun G, Wang J, Tang J, Chen M, Zhang Z, Zhao H, Jin Z, Xu X, Yang Y, Liu J. PMID: 42094612 [PubMed - indexed for MEDLINE]
	Local and systemic cytokine signatures for outcome prediction after transarterial chemoembolization in hepatocellular carcinoma. Theranostics Yilmaz EY, Schmidt R, Heidemann L, He Y, Liu Y, Sulejmani O, Müller DN, Wilhelm A, Auer TA, Hamm CA, Abosabie SAS, Abosabie SA, Gebauer B, Savic LJ. PMID: 42094598 [PubMed - indexed for MEDLINE]
	Clinical Setting Modulates the Association Between Genetic Variants and Fibrosis Severity Across the Spectrum of MASLD. Liver Int Lee MH, Stepanova M, Estep M, You YL, Liu XR, de Avila L, Lam B, Yu ML, Younossi ZM. PMID: 42093660 [PubMed - indexed for MEDLINE]
	Faecal Cathepsin B and S Are Associated With Liver Disease Severity and Adiposity in MASLD. Liver Int Harberts A, Fondevila MF, Kreimeyer H, Miwa T, Lang S, Demir M, Schnabl B. PMID: 42093609 [PubMed - indexed for MEDLINE]
	Fenugreek seed extract-doxorubicin synergy against hepatocellular carcinoma in HepG2 cells: in vitro and in silico mechanistic studies. BMC Complement Med Ther Ragab W, Mahmoud K, Allam RM, Qayed WS, Gomaa OM, El-Hawary SS, Moawad AS, Mohammed R. PMID: 42092913 [PubMed - indexed for MEDLINE]
	Sintilimab (PD-1 inhibitor) plus lenvatinib as conversion therapy followed by sequential surgery (SILENSES) for advanced unresectable hepatocellular carcinoma: a phase II, expansion trial. Signal Transduct Target Ther Lu S, Zhang W, Li J, Zhang Z, Hu B, Li X, Cao Y, Wang Z, Wang Z, Ye H, Qu B, Li Y, Ma G, Wan T, Liu Z, Liu B, Xu Y, Tang H, Zhao X, Pan L, Yang L, Yuan J, Chen R, Bian X. PMID: 42091859 [PubMed - indexed for MEDLINE]
	The Dual Role of Saikosaponins in Liver Disease Treatment: A Comprehensive Review of Pharmacological Activities and Toxicological Characteristics. Biol Pharm Bull Zhu S, Hao D, Mao B, Hua Y, Wang B, Wang P, Yuan W. PMID: 42091451 [PubMed - indexed for MEDLINE]
	Nutritional Risk Assessed by Royal Free Hospital-Nutritional Prioritizing Tool Predicts Survival in Cirrhosis With or Without Hepatocellular Carcinoma. J Korean Med Sci Park HJ, Jung JK, Noh J, Kim Y, Lee SU, Yun BC, Lee JW, Kim HJ, Seo KI. PMID: 42089136 [PubMed - indexed for MEDLINE]
	Integrated transcriptomic and single cell analysis combined with artificial neural network identifies a robust gene signature for early discrimination of MASL and MASH. Front Immunol Lin GW, Lin ZY, Su QY, Ye L, Xu WN, Nong SQ, Wu RK, Zhou WJ, Huang QF. PMID: 42088521 [PubMed - indexed for MEDLINE]
	Epigenetic reprogramming of hepatic antigen presenting cells in chronic liver disease. Front Immunol Ángel-Gomis E, Juanola O, Caparrós E, Francés R. PMID: 42088501 [PubMed - indexed for MEDLINE]
	Exercise Impacts Liver Disease: Balancing Metabolic and Immune Homeostasis. Int J Biol Sci Cheng C, Xu W, Wu S, Gao J, Huang J, Dong Y, Ji J, Zuo L, Wang H. PMID: 42088433 [PubMed - indexed for MEDLINE]
	Research Progress on Nanoformulations Based on Active Components from Traditional Chinese Medicine for MASLD. Int J Nanomedicine Gou ZX, Li NW, Yao JY, Wang YL. PMID: 42088396 [PubMed - indexed for MEDLINE]
	Splenic Marginal Zone Lymphoma as a Vascular-Appearing Mass in a Patient With Sustained Virologic Response to Hepatitis C Therapy. Am J Case Rep Tan XHI, Yee HN, Kwan KWC, Tan AYH, Kok S, Tan MO. PMID: 42087428 [PubMed - indexed for MEDLINE]
	Prevalence and Prognostic Impact of the Coexistence of Cachexia and Sarcopenia in Patients With Chronic Liver Diseases. J Cachexia Sarcopenia Muscle Tanaka T, Suda G, Ohara M, Yokoyama D, Kitano S, Maehara O, Yoda T, Fu Q, Yang Z, Yasuura N, Meno A, Sasaki T, Kohya R, Kitagataya T, Kawagishi N, Nakai M, Sho T, Ohnishi S, Sakamoto N. PMID: 42087383 [PubMed - indexed for MEDLINE]

Artikel 1 - 20 / 254949

Seite 1 von 12748



		Zeitfenster

Ironmedline

Das Fachportal für Eisenmangel >>

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung